- Home
- INKT vs BRNS Comparison
INKT vs BRNS Comparison
Compare INKT & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | BRNS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 55.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INKT | BRNS |
|---|---|---|
| Price | $10.26 | $0.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $4.00 |
| AVG Volume (30 Days) | 4.6K | ★ 64.0K |
| Earning Date | 03-23-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,969,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1766.46 |
| 52 Week Low | $6.66 | $0.56 |
| 52 Week High | $76.00 | $2.91 |
Technical Indicators
Market Signals| Indicator | INKT | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 39.03 |
| Support Level | $6.85 | $0.56 |
| Resistance Level | $12.78 | $0.76 |
| Average True Range (ATR) | 0.36 | 0.07 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 11.27 | 15.30 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.